APDN Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
January 5, 2023
LineaRx Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
September 30, 2022
LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development
July 25, 2022
APDN and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy
February 17, 2022
APDN Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch
June 7, 2021
APDN, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines
May 6, 2021
APDN, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate
November 30, 2020
APDN and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate
September 16, 2020
LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction
September 19, 2019
LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines
September 20, 2018